Elevated ALDH1 activity has been used as a cancer stem cell biomarker of tumor aggressiveness in the invasive front of NPC [20], while a lower expression of ALDH2 has been associated with poor prognoses in breast cancer, lung adenocarcinoma, and HNC squamous cell carcinomas [21]. This evidence concerns the gene ALDH2 and breast carcinoma.